Brokerages Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $76.17

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $76.17.

Several research analysts have weighed in on the company. Citigroup assumed coverage on Structure Therapeutics in a report on Friday, May 2nd. They issued a “buy” rating and a $60.00 price target for the company. HC Wainwright cut their price target on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a report on Monday, May 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, June 23rd. Finally, JMP Securities reiterated a “market outperform” rating and issued a $89.00 price target on shares of Structure Therapeutics in a report on Monday, June 23rd.

Structure Therapeutics Stock Performance

GPCR stock opened at $17.83 on Monday. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $45.37. The stock’s 50 day moving average price is $20.71 and its 200 day moving average price is $22.33. The firm has a market cap of $1.02 billion, a P/E ratio of -20.49 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.03). On average, research analysts predict that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC increased its holdings in shares of Structure Therapeutics by 5.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock worth $112,816,000 after buying an additional 203,010 shares during the last quarter. Deep Track Capital LP increased its holdings in shares of Structure Therapeutics by 129.4% during the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company’s stock worth $75,936,000 after buying an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Structure Therapeutics by 3.7% during the 1st quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company’s stock worth $30,967,000 after buying an additional 63,990 shares during the last quarter. Capital International Investors increased its holdings in shares of Structure Therapeutics by 6.8% during the 4th quarter. Capital International Investors now owns 1,619,081 shares of the company’s stock worth $43,909,000 after buying an additional 103,059 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Structure Therapeutics by 29.4% during the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company’s stock worth $38,512,000 after buying an additional 322,601 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.